Endocyte, Inc.
1205 Kent Avenue
West Lafayette, Indiana 47906
Phone 765.463.7175
FAX 765.463.9271
 |
Endocyte, Inc.1205 Kent Avenue |
|
Endocyte is committed to use a new generation of receptor-targeted therapeutics as “Trojan horses” to target and deliver diagnostic and therapeutic agents into diseased cells for the treatment of cancer and autoimmune diseases.
P. Ron Ellis, MBA
CEO & President
Christopher P. Leamon, PhD
V P - Research and Development
Teri F. Willey, MBA
Director Business Development
Allen Ritter, PhD
Director Development
Gretchen Miller Bowker, MS, RAC
Director Regulatory Affairs
Endocyte was founded in 1996 as a biotechnology company specializing in developing a new generation of receptor-targeted therapeutics, or smart drugs, for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are toxic to normal healthy cells, causing serious side effects. These side effects can be life-threatening, resulting in sub-optimal dosing. Receptor-targeted therapeutics prove more effective because they can be targeted with lethal precision to high affinity receptors over-expressed by diseased cells.
Endocyte’s initial focus is on a receptor over-expressed on cancer cells for the vitamin folic acid. By attaching drugs to folic acid, the vitamin targets and delivers drugs to cancer cells, thus allowing higher and more effective doses to be given with reduced side effects. Endocyte is using folate to target:
Endocyte is headquartered in the Purdue Research Park in West Lafayette, Indiana. The company has exclusive worldwide license to Purdue University’s patents on vitamin use for cellular targeting and uptake. They are a leader of the Indiana Drug Delivery Consortium.
A member of the Life Science Research Council (LSRC).